News Center

Peijia Medical Announces First Patient Implant in the Clinical Trial of its Third-Generation Transcatheter Aortic Valve System TaurusNXT®

2021-09-14

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant To Advise the Company’s Mitral Transcatheter Edge-to-edge Repair Project and the Company in General

2021-09-06

Peijia Medical Announces 2021 Interim Results

2021-08-31

TaurusOne Valve clinical outcome published in EuroIntervention

2021-08-09

With the second-generation transcatheter aortic valve replacement system approved for marketing, Peijia Medical leads China into the “Retrievable Era” using TAVR products

2021-06-26

Peijia Medical and CR PHARMA COMM Sign Memorandum of Strategic Cooperation

2021-06-25

Peijia Medical Partners with inQB8 for US Incubator and Transcatheter Tricuspid Replacement (TTVR) Product

2021-06-10

Peijia Medical and CR PHARMA COMM Sign Memorandum of Strategic Cooperation

2021-06-04

Peijia Medical’s TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization

2021-04-26

Patient Enrollment Completed for Clinical Trial of Peijia Medical’s Shenyi® Stent Retriever

2021-02-01

Collaboration Strengthens Peijia’s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife’s Technology

2020-12-21

Peijia Medical Successfully Commenced Animal Study for its Mitral Valve Edge-to-Edge Repair Product

2020-12-04

Peijia Medical Successfully Listed on the Main Board of the Stock Exchange of Hong Kong

2020-05-15

Peijia Medical Announces Global Offering Results Offer Price is HK$15.36 per Offer Share, Commence Trading on the Main Board of the Hong Kong Stock Exchange On May 15, 2020

2020-05-14

Peijia Medical Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

2020-05-05